-transparent.png){kind=logo}
Between May 1978 and March 1982, 179 postmenopausal women with operable breast cancer were randomized to receive either adjuvant tamoxifen, 40 mg daily for three years (TAM group), or no further treatment (controls). The difference in five-year survival rates (61% in the control group, 72% in the TAM group) was not statistically significant. However, there was a significant improvement in disease-free survival in the TAM group (61%) relative to the controls (44%) (p = 0.008). In estrogen receptor positive patients, tamoxifen improved both the disease-free rate (47% controls, 80% with tamoxifen) and the survival rate (63% to 83%). Similar results were observed in progesterone receptor positive patients. In patients that were estrogen receptor negative, tamoxifen modified neither the survival rate nor the disease-free interval.
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
January 1992,
Acta oncologica (Stockholm, Sweden),
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
July 1990,
Cancer,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
October 2000,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
May 1997,
Journal of the National Cancer Institute,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
January 1993,
European journal of cancer (Oxford, England : 1990),
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
May 2000,
Annals of oncology : official journal of the European Society for Medical Oncology,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
September 2002,
Annals of oncology : official journal of the European Society for Medical Oncology,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
November 1996,
Journal of the National Cancer Institute,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
December 1985,
Journal of steroid biochemistry,
T Delozier, and
J P Julien, and
P Juret, and
C Veyret, and
J E Couëtte, and
Y Graic, and
J M Ollivier, and
E de Ranieri
January 2019,
Cancer management and research,
